Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBIT Margin: 2011-2025

Historic EBIT Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -140.69%.

  • Iovance Biotherapeutics' EBIT Margin rose 1142.00% to -140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -166.31%, marking a year-over-year increase of 30691.00%. This contributed to the annual value of -240.92% for FY2024, which is 3849407.00% up from last year.
  • Iovance Biotherapeutics' EBIT Margin amounted to -140.69% in Q3 2025, which was up 25.87% from -189.78% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBIT Margin ranged from a high of -117.48% in Q4 2024 and a low of -46,254.62% during Q2 2023.
  • Moreover, its 3-year median value for EBIT Margin was -286.70% (2024), whereas its average is -11,428.64%.
  • Data for Iovance Biotherapeutics' EBIT Margin shows a peak YoY skyrocketed of 4,592,699bps (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' EBIT Margin (Quarterly) stood at -25,156.85% in 2023, then soared by 2,503,937bps to -117.48% in 2024, then surged by 1,142bps to -140.69% in 2025.
  • Its last three reported values are -140.69% in Q3 2025, -189.78% for Q2 2025, and -245.76% during Q1 2025.